Anabolic Properties of Canola (ALPACA)

May 15, 2023 updated by: Maastricht University Medical Center

The Evaluation of Canola Protein and Whey Protein to Support Muscle Conditioning in Vivo in Young Females

Muscle tissue consists of proteins. These proteins are built up of small building blocks: amino acids. By consuming enough protein in our diet, we make sure that the body is provided with enough amino acids to facilitate muscle protein building. Also after exercise is protein intake important as it contributes to the recovery process. Providing the growing world population with sufficient animal-derived protein is a challenge. Plant proteins can be produced on a more sustainable commercial scale than conventional animal-derived proteins and therefore, can contribute to feeding our future population. Canola protein is a protein that is derived from rapeseed. The composition of canola seems to be comparable to that of other high-quality animal-based protein sources. But there is no data yet on the effect of canola protein ingestion on muscle growth. Additionally, most research on the effect of protein intake and muscle growth/recovery has been performed in males and we need more insight into the effect in females. The goal of this study is to investigate whether the ingestion of canola protein can stimulate muscle growth just as good as whey protein after a strength exercise session in females.

Primary objective: To assess the impact of 20g canola or 20g whey protein vs placebo ingestion on acute 5-hour postprandial muscle protein synthesis rates during recovery from lower-body resistance-type exercise in vivo in young females.

Secondary objective: To assess the impact of 20g canola protein vs 20g whey protein ingestion on acute 5-hour postprandial muscle protein synthesis rates during recovery from lower-body resistance-type exercise in vivo in young females.

Tertiary objectives: Compare signaling pathways and. postprandial 5-hour plasma glucose, insulin, and amino acid concentrations, (including area under the curve, peak concentrations, and time to peak) following canola protein, whey protein, and placebo ingestion during recovery from lower-body resistance-type exercise in young females.

Hypothesis: it is hypothesized that acute 5-hour postprandial muscle protein synthesis rates will be not different following 20g canola protein and 20g whey protein ingestion and higher compared to placebo during lower-body post-exercise recovery in healthy young females.

Study Overview

Detailed Description

Screening and pre-testing To assess whether volunteers are eligible to participate in this study, we will invite them to the University for a screening. At the start of the screening session, the entire experimental trial will be explained and any potential questions will be answered. Thereafter, the volunteers are asked to read, fill out, and sign the informed consent form. After signing the informed consent form, the participant's eligibility will be assessed based on the in- and exclusion criteria. To further assess their eligibility, participants will be asked to fill out a medical questionnaire to assess their general health, use of medication, habitual food intake, and physical activity (Appendix F1.1). Next, blood pressure will be assessed. Body mass (with accuracy of 0.1 kg) and height (with accuracy of 0.01 m) will be determined, and body composition will be assessed via a Dual Energy X-ray Absorptiometry (DEXA) scan. A DEXA scan is a simple, non-invasive procedure. At the beginning of the procedure, subjects will be asked to lie down on a scanning table wearing underwear and they need to remain motionless during the measurements. As the scanner moves, a dual energy beam passes through the targeted skeletal muscle section and is measured by a detector. This procedure is repeated until the whole body is scanned and takes approximately 3 minutes.

The screening sessions will take place in the morning and participants are instructed to not have any breakfast in the morning in order to avoid perturbations in the DEXA scan.

In the event of an unexpected medical finding during the screening, subjects will always be notified. If a subject does not want to receive this notification, she cannot participate in the study.

Next, subjects will be familiarized and tested for bilateral strength on the exercise machines. First, participants will warm up on a cycle ergometer for 5 minutes at 100W. Subjects will be instructed on proper weight-lifting technique on each exercise machine (leg-press and leg-extension) and complete a standardized testing protocol to determine a measurement of maximal strength (1RM) for each exercise machine. In short, subjects will be seated on a leg press and leg extension machine and start with a warm-up of 2 sets of 10 repetitions with self-chosen weights. Then the load will be increased above the warming-up weight. The load will be increased after each successful lift, until failure, to determine maximal strength. A repetition is classified as "valid" if the participant is able to complete the entire lift in a controlled manner, without assistance.

When the screening is successfully performed, the test day will be scheduled. In order to prevent major impact from the menstrual cycle on the measurements of protein metabolism, the test day will be scheduled to take place in the first 10 days of the follicular phase.

Each subject will participate in an experimental trial lasting ~9h. Subjects will be instructed to arrive at the university at 7:45 AM in an overnight fasted and rested state, meaning that participants are not allowed to eat and drink (except for water) from 22:00 the night prior to the experimental trial. They will be instructed to come to the university by car or public transportation. After the subjects arrive at the University, we will ask them to put on their shorts, determine their body mass, and assign them to a bed. Subjects will rest in a supine position and a Teflon catheter will be inserted in a heated dorsal hand vein and placed in a hot-box (60°C) for arterialized blood sampling. A baseline blood sample (Serum + plasma = 20 mL) will be collected at t= -210min to determine the amino acid enrichment level prior to the intervention. Following basal blood sample collection, a second Teflon catheter will be inserted into an antecubital vein of the contralateral arm for stable isotope infusion with the amino acids 13C6-phenylalanine and 2H2-tyrosine. At the start of the isotope infusion, the plasma phenylalanine and tyrosine pools will be primed with a single dose of the tracer solution, directly thereafter the continuous tracer infusion will commence.

During the entire experimental test day, the hand with the dorsal hand catheter will be pre-heated for 10 minutes prior to every blood draw in a hot box at 60°C to increase blood flow. This makes it easier to collect blood and minimizes nutrient exchange from blood into other tissues. Therefore, it allows us to collect nutrient-rich (arterialized) blood from a vein. Arterialized blood samples (10mL) will be collected at t = -180, -120, -60, and 0 min to assess plasma tracer enrichments during the tracer infusion in the resting overnight post-absorptive period. After a pre-infusion period of 30 minutes (t = -180), during which the tracer infusion reaches steady state, a first muscle biopsy will be taken from the m. vastus lateralis to determine the background enrichment. At t=-45 min, a resistance-type exercise session will be performed (40 minutes). Subsequently, at t= 0 min a second biopsy will be taken from the same leg in order to assess the basal muscle protein synthetic rate. Immediately after the second biopsy, subjects will ingest the assigned drink (20g canola or whey protein or a non-caloric placebo). Subjects will be instructed to consume the drink within ~5 min.

Upon drink ingestion, the stopwatch will be reset (t= 0 min), and arterialized blood samples (10 mL) will be collected at t = 30, 60, 90, 120, 180, 240, and 300 min during the post-prandial period to assess plasma amino acid profiles and enrichments. To determine postprandial muscle protein synthesis (MPS), another biopsy will be taken at t = 300 min following meal ingestion from the contra-lateral leg. The muscle biopsy at t = 300 min allows us to obtain physiological relevant information with regard to the duration of the anabolic response to protein intake over a commonly used 5h postprandial period. Collectively, with the obtained biopsies we can measure muscle protein synthesis in the resting state (-180 - 0 min) and entire postprandial period (0 - 300 min; main outcome).

During the test day, a total of 3 muscle biopsies will be taken through 3 separate incisions, 2 biopsies from the one leg and 1 biopsy from the other leg. In total 12 times blood samples will be taken during the test day, the first sample that will be collected will be 20mL the subsequent samples 10mL, for a total of 130mL. Additionally, gastro-intestinal (GI) symptoms will be assessed at t = -60, 30, and 180 minutes and palatability at t = 15 min by questionnaires

Study Type

Interventional

Enrollment (Anticipated)

36

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Limburg
      • Maastricht, Limburg, Netherlands, 6229ER

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 33 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Female sex
  • Aged between 18 and 35 y inclusive
  • BMI between 18.5 and 30 kg/m2

Exclusion Criteria:

  • Intolerant to milk products
  • Mustard allergy
  • Participating in a structured (progressive) exercise program
  • Smoking regularly
  • Diagnosed GI tract disorders or diseases
  • Diagnosed musculoskeletal disorders
  • Diagnosed metabolic disorders (e.g. diabetes)
  • Hypertension (blood pressure above 140/90 mmHg)
  • Donated blood 3 months prior to test day
  • Pregnant
  • Using third generation oral contraceptives
  • Use of any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories).
  • Chronic use of gastric acid suppressing medication
  • Chronic use of anti-coagulants
  • Recent (<1 year) participation in amino acid tracer (L-[ring-13C6]-phenylalanine and L-[3,5-2H2]-tyrosine studies

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Canola protein
20g of canola protein
drink ingestion of a vanilla-flavoured beverage from a non-transparent shaker
Other Names:
  • supplement
Lower body resistance-type exercise on the supine leg press and seated knee extension machine. Both machines 4 sets at 80% 1RM for 8-10 reps.
Other Names:
  • strength training
  • resistance training
Active Comparator: Whey protein
20g of whey protein
drink ingestion of a vanilla-flavoured beverage from a non-transparent shaker
Other Names:
  • supplement
Lower body resistance-type exercise on the supine leg press and seated knee extension machine. Both machines 4 sets at 80% 1RM for 8-10 reps.
Other Names:
  • strength training
  • resistance training
Sham Comparator: Placebo
Water, matched for taste and volume
drink ingestion of a vanilla-flavoured beverage from a non-transparent shaker
Other Names:
  • supplement
Lower body resistance-type exercise on the supine leg press and seated knee extension machine. Both machines 4 sets at 80% 1RM for 8-10 reps.
Other Names:
  • strength training
  • resistance training

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postprandial muscle protein fractional synthesis rate
Time Frame: 0-5 hours
Muscle protein synthesis rates are calculated using L-ring-13C6-phenylalanine tracer and provided as 1 integrated value over the specified timeframe using plasma as precursor.
0-5 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plasma glucose concentrations
Time Frame: 0-5 hours
Plasma glucose concentrations
0-5 hours
Plasma insulin concentrations
Time Frame: 0-5 hours
Plasma insulin concentrations
0-5 hours
Plasma amino acids concentrations
Time Frame: 0-5 hours
Plasma amino acids concentrations
0-5 hours
'basal' muscle protein fractional synthesis rate
Time Frame: -3 - 0 hours
Muscle protein synthesis rates are calculated using L-ring-13C6-phenylalanine tracer and provided as 1 integrated value over the specified timeframe using plasma as precursor.
-3 - 0 hours

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Age in years
Time Frame: baseline at screening
Age in years reported by participants
baseline at screening
bodymass in kg
Time Frame: baseline at screening
scale
baseline at screening
Height in m
Time Frame: baseline at screening
stadiometer
baseline at screening
BMI in kg/m^2
Time Frame: baseline at screening
calculated from height and body mass
baseline at screening
Whole body lean mass in kg
Time Frame: baseline at screening
dexa
baseline at screening
Appendicular lean mass in kg
Time Frame: baseline at screening
dexa
baseline at screening
bodyfat%
Time Frame: baseline at screening
dexa
baseline at screening
Dietary macronutrient intake
Time Frame: 2 days prior to experimental trial day
assessed by written dietary intake records
2 days prior to experimental trial day
Maximal leg strength
Time Frame: baseline at screening
1-Repetition-maximum assessed on leg press and knee extension
baseline at screening
drink palatability
Time Frame: On experimental trial day directly after drink ingestion
Assessed by a visual analogue scale after drink ingestion
On experimental trial day directly after drink ingestion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Luc van Loon, PhD, Maastricht University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 20, 2023

Primary Completion (Anticipated)

August 1, 2024

Study Completion (Anticipated)

August 1, 2024

Study Registration Dates

First Submitted

November 22, 2022

First Submitted That Met QC Criteria

December 16, 2022

First Posted (Actual)

December 23, 2022

Study Record Updates

Last Update Posted (Actual)

May 17, 2023

Last Update Submitted That Met QC Criteria

May 15, 2023

Last Verified

December 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • NL81203.068.22 / METC 22-031

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Muscle Protein Synthesis

Clinical Trials on drink ingestion

3
Subscribe